08:26 AM EDT, 05/09/2024 (MT Newswires) -- Amicus Therapeutics ( FOLD ) reported a Q1 non-GAAP net loss Thursday of $0.02 per diluted share, compared with a loss of $0.06 a year earlier.

Analysts surveyed by Capital IQ expected a loss of $0.03.

Net product sales for the quarter ended March 31 were $110.4 million, compared with $86.3 million a year earlier.

Analysts surveyed by Capital IQ expected $111.2 million.